In short
DCC-3084 is an investigational drug currently being studied in clinical trials for patients with advanced cancers that are driven by the MAPK pathway. This multicenter, Phase 1/2 clinical trial is evaluating DCC-3084 both as a standalone treatment and in combination with other cancer therapies. The study primarily focuses on patients with advanced or metastatic solid tumors, with a particular interest in specific cancer types including non-small cell lung cancer, pancreatic ductal adenocarcinoma, melanoma, and castration-resistant prostate cancer. The trial is especially targeted at cancers with specific genetic mutations, such as BRAF, CRAF, RAS, and NF1 mutations, which affect the MAPK pathway that regulates cell growth and division.
Key points
- DCC-3084 is a novel drug currently being evaluated in a Phase 1/2 clinical trial for patients with advanced cancers driven by abnormalities in the MAPK pathway. The trial focuses on patients with specific genetic mutations (BRAF, CRAF, RAS, NF1) and various cancer types including non-small cell lung cancer, pancreatic cancer, and melanoma. This oral medication is being tested both alone and in combination with other cancer therapies. The study aims to determine the appropriate dose, assess safety, and measure effectiveness through response rates and survival times. The trial is structured with an initial dose escalation phase followed by a dose expansion phase to further evaluate promising results.
At a glance
- Drug Name
- DCC-3084
- Administration Method
- Oral
- Study Phase
- Phase 1/2
- Study Design
- Multicenter, multi-cohort, open-label with dose escalation and expansion phases
- Target Condition
- Advanced malignancies driven by the MAPK pathway
- Specific Cancer Types
- Advanced solid tumors, non-small cell lung cancer, pancreatic ductal adenocarcinoma, melanoma, castration-resistant prostate cancer
- Genetic Mutations of Interest
- BRAF, CRAF, RAS, NF1
- Primary Outcomes
- Dose-limiting toxicities (Part 1), Objective response rate (Part 2)
- Secondary Outcomes
- Objective response rate (Part 1), progression-free survival, overall survival, pharmacokinetics
- Treatment Approach
- DCC-3084 as monotherapy and in combination with other antitumor agents
- Current Status
- Module A enrolling participants with advanced/metastatic solid tumors; additional modules may be added
What is DCC-3084?
DCC-3084 is a new investigational medication being studied for the treatment of advanced cancers that are driven by specific genetic changes in what's called the MAPK pathway. The MAPK (Mitogen-Activated Protein Kinase) pathway is a chain of proteins in your cells that communicates signals from the cell surface to the DNA in the cell nucleus. When this pathway has certain mutations or abnormalities, it can lead to uncontrolled cell growth, which is a hallmark of cancer.
This medication is currently being tested in clinical trials to determine its safety and effectiveness. It can be given alone (called monotherapy) or in combination with other cancer treatments.
How DCC-3084 Works
While the exact mechanism isn't fully detailed in the available information, DCC-3084 appears to target the MAPK pathway, which is involved in cell growth and division. Many cancers have mutations in this pathway, particularly in genes called RAF (including BRAF and CRAF), RAS, and NF1.
By targeting this pathway, DCC-3084 may help to slow or stop the growth of cancer cells that depend on these genetic mutations to survive and spread. This targeted approach is part of a growing trend in cancer treatment called precision medicine, where treatments are designed to address specific genetic changes in a person's cancer.
What Conditions Does DCC-3084 Treat?
DCC-3084 is being studied for several types of advanced cancers, particularly those with specific genetic mutations. These include:
- Advanced solid tumors - These are cancers that form solid masses and have spread beyond their original location
- Non-small cell lung cancer - The most common type of lung cancer
- Pancreatic ductal adenocarcinoma - The most common type of pancreatic cancer
- Melanoma - A serious type of skin cancer
- Castration-resistant prostate cancer (CRPC) - An advanced form of prostate cancer that continues to grow despite treatments that lower testosterone
Specifically, DCC-3084 targets cancers with mutations in the following genes:
- BRAF gene mutations - Common in melanoma and some other cancers
- CRAF gene mutations - Another type of RAF mutation found in various cancers
- RAS mutations - Common in pancreatic cancer and other cancers
- NF1 mutations - Can occur in various cancer types
Current Clinical Trial Information
DCC-3084 is currently being studied in a multicenter, Phase 1/2 clinical trial. The study is organized as follows:
- It's designed as a "master protocol" with different modules for different cancer types
- Currently, Module A is enrolling participants with advanced/metastatic solid tumors
- Additional modules exploring other cancers may be added later
Each module is conducted in two parts:
- Part 1 (Dose Escalation) - This phase is designed to find the safest and most effective dose of the medication
- Part 2 (Dose Expansion) - This phase further tests the selected dose in more patients
How DCC-3084 is Administered
DCC-3084 is administered orally, which means it's taken by mouth as a pill or capsule. This is more convenient than some cancer treatments that require intravenous (IV) administration in a clinic or hospital setting. The specific dosing schedule and instructions would be provided to participants in the clinical trial.
Expected Outcomes and Measurements
The clinical trial is measuring several important outcomes to determine if DCC-3084 is safe and effective:
Primary Outcomes:
- Safety - In Part 1, researchers are looking at the number of participants who experience Dose-limiting Toxicities (DLTs), which are serious side effects that might limit the use of the drug
- Effectiveness - In Part 2, they're measuring the Objective Response Rate (ORR), which is the percentage of participants whose cancer shrinks or disappears after treatment
Secondary Outcomes:
- Objective Response Rate in Part 1 participants
- Progression-Free Survival (PFS) - The time from the start of treatment until the cancer grows or spreads, or the patient dies
- Overall Survival (OS) - The time from the start of treatment until death from any cause
- Pharmacokinetics - How the drug moves through the body, including measurements like the maximum concentration of the drug in the blood (Cmax)
These measurements will help determine whether DCC-3084 should move forward in the development process and potentially become available as a treatment option for patients with these types of cancers.